Phase 3 trial shows 51 percent reduction in the risk for disease progression or death in triple-class exposed patients
TUESDAY, April 9, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
The approval is for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is a one-time infusion, with a new recommended dose range of 300 to 510 x 106 CAR-positive T cells. Boxed warnings for Abecma include cytokine release syndrome, neurologic toxicities, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, prolonged cytopenia, and secondary hematological malignancies.
The approval was based on data from the phase 3 KarMMa-3 trial of 254 patients. At a median follow-up of 15.9 months, Abecma more than tripled the primary end point of progression-free survival versus standard regimens, with a median progression-free survival of 13.3 months versus 4.4 months (hazard ratio, 0.49). Overall response rates were also significantly improved with Abecma, with 71 percent of patients treated with Abecma achieving a response and 39 percent achieving a complete or stringent complete response compared with 42 and 5 percent, respectively, of those receiving standard regimens. Responses to Abecma were durable, with a median duration of response of 14.8 months (or 20 months for patients who derived a complete response or better).
“With this approval, these patients now have an opportunity to be treated at an earlier line of therapy with a potentially transformative therapy that offers significantly improved progression-free survival for this difficult-to-treat disease that has had no established treatment approach,” Al-Ola A. Abdallah, M.D., chair of the U.S. Myeloma Innovations Research Collaborative, said in a statement.
Approval of Abecma was granted to Bristol Myers Squibb and 2seventy bio.
Most Speakers at FDA Advisory Committee Meetings Support Drug Approval 
Countries Involved in U.S. Clinical Trials Do Not Gain Timely Access to Approved Medicines 
FDA Picks George Tidmarsh to Head Center for Drug Evaluation and Research 
Approved-Label Populations for New Drugs Broader Than Trial Populations 
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing 
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors 
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV .jpg)
